CoSara Diagnostics Observes World Cancer Day with Cancer Awareness Event

The Union for International Cancer Control’s World Cancer Day (WCD), observed every February 4, was established in the year 2000 “to raise awareness about cancer, encourage its prevention, and mobilize action to address the global cancer epidemic.” The current WCD theme, “United by Unique,” reminds us that every diagnosis is unique , and that it will take a world united to make a difference.

In keeping with this theme, and with the goals of WCD to catalyze personal, collective and government action and of working together in our respective roles to reduce the global impact of cancer, CoSara Diagnostics and the Ambalal Sarabhai Foundation were proud to host a lecture series on holistic cancer awareness. The lecture series brought together participants and speakers on February 4 th in Vadodara, Gujarat to shed light on the topics of prevention, diagnosis and nutrition.

After a welcoming address by Dr. Ashtaad Vesuna of CoSara Diagnostics, the first speaker at the event was Dr. Krish Vaidya, M.D., Consultant Cardiologist iCure Healthcare Pvt. Ltd. Dr. Vaidya’s remarks, titled “ Cancer and Diet: Diets that Cause Cancer & Diet to Fight Cancer ,” were followed by Dr. Udayan Kachhi, M.D. Dr. Kachhi, Consultant Pathologist Dr. Udayan’s Lab/Pranayam Hospital/Aadicura Hospital, spoke on the topic of “ The Pathologist’s Role: From Biopsy to Diagnosis .”

The third speaker on the schedule was Dr. Swati B. Patel, P.G.D., Dietitian/Nutritionist at the Body Tune Weight Loss Centre in Vadodara, who spoke about “ Dietary Strategies to Improve Quality of Life in Cancer Patients .”

CoSara’s own Ms. Julia M. Tahilramani shared a research outline about CoSara’s commitment towards cancer, before CoSara Chief Operating Officer Mr. Anurag Mehta concluded the evening with a vote of thanks to the attendees.

Cervical cancer, the fourth most common cancer in women, led to an estimated 350,000 deaths in 2022 according to the WHO . The National Cancer Institute estimates that high-risk HPVs cause roughly 5% of all cancers worldwide, including cervical cancer. Early HPV diagnosis not only helps carriers of the virus to be aware that they are now at risk of passing it to others; it can also trigger patients to begin regular screenings of cervical and other cancers, allowing them to be caught far earlier and promoting improved outcomes.

Co-Diagnostics and CoSara are committed to a future with equitable access to infectious disease diagnostics. CoSara’s Saragene® Human Papillomavirus-High Risk real-time PCR IVD is already used in clinical laboratories in India to detect and differentiate HPV genotypes 16 and 18. Co-Dx is also developing a multiplex PCR HPV test for use on its upcoming Co-Dx PCR platform* for use in point-of-care locations (from hospitals, to doctors’ offices, to local clinics around the world) to increase access to this game-changing diagnostic.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale